[News Article]PharmAbcine`s ``BI(Business Incubation) Research Grant`` proposal is granted by KIAT.
Dr. Lawrence Cher at Olivia Newton-Johns Cancer Wellness & Research Center/Austin Hospital is invited to present the interim data of Tanibirumab phase IIa recurrent GBM trial...
Dr. Jin-San Yoo, CEO of PharmAbcine is invited to present for ``Investor Relation`` at MIRAE ASSET DAEWOO SECURITIES Corporate Day on July 12th, 2017.
PharmAbcine`s "BI(Business Incubation) Research Grant" proposal is granted by KIAT (https://www.kiat.or.kr/site/main/main.jsp) and PharmAbcine will use this research funding to generate the second generation of PMC-001(DIG-KT) to get ready to out-license.
The first generation version of PMC-001(DIG-KT) has been out-licensed to 3SBio for both Korea and China market in 2015.The CEO and CFO of PharmAbcine are going to participate the BI Research Grant workshop organized by KIAT and will have 1-to 1 partnering meetings with investors and business partners on July 13-14, 2017.
Reference:
http://www.prnewswire.com/news-releases/3sbio-signs-exclusive-patent-license-agreement-for-dig-kt-a-bi-specific-mab-targeting-vegfr2-and-tie-2-with-pharmabcine-300020495.html
http://bciq.biocentury.com/products/dig-kt
http://whosaeng.com/sub_read.html?uid=71563
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3499296/
http://eng.kddf.org/bbs/bbs.asp?mode=view&IDX=717&p=1&cateId=35
http://www.worldbil.com/CTIP2015/Download/8.pdf